Osivax CEO Hopes Vaccines Maker Can Develop Universal Flu ‘Silver Bullet’

Emerging Company Profile: Osivax is using its oligoDOM technology platform to developer a vaccine pipeline. The French biotech aims to establish proof-of-concept in influenza A then expand the pipeline to provide a universal flu vaccine.

Emerging Company Profile Regular column feature image Version 2
Osivax has a universal flu vaccine candidate in pre-clinical development • Source: Shutterstock

French vaccines start-up Osivax was spun off from Imaxio SA in 2017 from which the company obtained its oligoDOM pro-immunogenic antigen re-engineering technology. The spin-off’s CEO Alexandre Le Vert told Scrip it plans to bring about a paradigm shift in the prevention of seasonal and pandemic influenza, and potentially develop a universal flu vaccine from its technology.

He said Osivax’s technology platform was 12 years in the making and provides a versatile basis to trigger effective immune...

Welcome to Scrip

Create an account to read this article

More from Start-Ups & SMEs

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

 
• By 

Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

More from Business

J&J Delivers In Q2 Despite Stelara Drop, Raising Guidance

 

Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.

PureTech Ponders Way Forward As CEO Exits

 
• By 

Bharatt Chowrira departs days after firm’s chair stepped down.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?